Segment and Geographic Location Information (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Components of Segment Revenues and Adjusted EBITDA

Segment revenues and Adjusted EBITDA consisted of the following:

	Three Months Ended September 30,
	2023						2022
				Segment						Segment
	Segment			Adjusted			Segment			Adjusted
	Revenues			EBITDA			Revenues			EBITDA(4)
Assessment, Permitting and Response	$	57,009		$	14,878		$	46,414		$	9,820
Measurement and Analysis		50,468	(1)		10,352			43,754	(1)		8,483		(3)
Remediation and Reuse		60,460			7,446			40,144			7,010
Total Operating Segments		167,937			32,676			130,312			25,313
Corporate and Other		—			(9,373	)		—			(6,940	)
Total	$	167,937		$	23,303		$	130,312		$	18,373
	Nine Months Ended September 30,
	2023						2022
				Segment						Segment
	Segment			Adjusted			Segment			Adjusted
	Revenues			EBITDA			Revenues			EBITDA(4)
Assessment, Permitting and Response	$	170,634		$	42,977		$	142,051		$	30,252
Measurement and Analysis		143,050	(2)		27,528			125,739	(2)		21,852		(3)
Remediation and Reuse		144,782			18,767			137,112			22,059
Total Operating Segments		458,466			89,272			404,902			74,163
Corporate and Other		—			(28,175	)		—			(22,826	)
Total	$	458,466		$	61,097		$	404,902		$	51,337

_____________________________________

(1) Includes revenue of $2.0 million and $3.9 million from the Discontinuing Specialty Lab, for the three months ended September 30, 2023 and September 30, 2022, respectively.

(2) Includes revenue of $5.9 million and $12.9 million from the Discontinuing Specialty Lab, for the nine months ended September 30, 2023 and September 30, 2022, respectively.
(3) Includes Adjusted EBITDA loss of $(0.5) million and $(0.1) million from the Discontinuing Specialty Lab for the three and nine months ended September 30, 2022, respectively.

(4) Includes the add back of start-up losses and investment in new services of $1.3 million and $2.9 million for the three and nine months ended September 30, 2022, respectively.

Reconciliation of Segment Measure to Net Loss

Presented below is a reconciliation of the Company’s segment measure to net loss:

	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2023				2022				2023				2022
Total	$	23,303			$	18,373			$	61,097			$	51,337
Interest expense, net		(2,089	)			(1,400	)			(5,507	)			(4,010	)
Income tax (expense) benefit		(1,324	)			208				(2,842	)			(1,892	)
Depreciation and amortization		(11,863	)			(11,504	)			(33,816	)			(35,928	)
Stock-based compensation		(11,484	)			(11,018	)			(35,609	)			(32,375	)
Start-up losses and investment in new services		—				(1,278	)			—				(2,949	)
Acquisition costs		(1,499	)			(368	)			(4,970	)			(1,354	)
Fair value changes in financial instruments		(806	)			1,808				(1,814	)			4,664
Fair value changes in business acquisition    contingencies		(459	)			(59	)			(414	)			3,472
Expenses related to financing transactions		(3	)			—				(7	)			(7	)
Discontinuing Specialty Lab		(1,302	)	(1)		—				(5,321	)	(1)		—
Other gains (losses) and (expenses)		1				(482	)	(2)		(215	)			(1,965	)	(2)
Net loss	$	(7,525	)		$	(5,720	)		$	(29,418	)		$	(21,007	)

__________________________

(1) Amounts consist of operating losses before depreciation related to the Discontinuing Specialty Lab.

(2) Amounts include costs associated with the closing of a lab.

Schedule of Revenues by Geographic Location

The following table presents revenues by geographic location:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2023		2022		2023		2022
United States	$	133,451	$	124,677	$	405,395	$	389,954
Canada		31,206		3,361		44,488		8,486
Other international		3,280		2,274		8,583		6,462
Total Revenue	$	167,937	$	130,312	$	458,466	$	404,902